#Minato, Tokyo #Aging Care #Space Seed #Regenerosome

Regenerosome Achieves Milestone in Funding

Regenerosome, a startup focused on regenerative medicine and anti-aging technology under Space Seed Holdings, has successfully completed its Pre-Seed funding round, totaling 110 million yen. This achievement comes after securing a 30 million yen loan from an urban bank in May 2025. Additionally, this funding incorporates 80 million yen raised through a J-KISS type stock option with Japan System Technology Co., Ltd. in October 2024.

The funds raised will primarily be allocated to advancing Regenerosome's healthcare business while leveraging its headquarters and research facility, the Takanawa Longevity Lab (LiSH), launched in May 2025 at the Takanawa Gateway Link Scholars’ Hub. This facility acts as a vibrant startup ecosystem operated by East Japan Railway Company, supporting over 100 startups in various fields, including deep tech. More information can be found at LiSH Website.

With the closure of its Pre-Seed round, Regenerosome is now turning its focus to preparations for their next fundraising round scheduled for October 2025 to March 2026. Until September 2025, the company will accelerate both research and business operations while actively engaging in discussions with potential funding candidates.

Accelerating Research and Development

Collaborating with Tohoku University, Regenerosome has initiated a study utilizing LiSH's analytical equipment to comprehensively analyze aging markers and epigenetic indicators. This research aims to explore the reversibility of aging.

In partnership with Good Hero Therapeutics, a company recognized by AMED, Regenerosome is also co-developing gene technologies related to aging care using viral vectors. Plans are in place to apply drug delivery systems (DDS) technologies through the use of nanoparticles and liposomes.

Development of Aging Care Ingredients

Regenerosome is actively extracting and elucidating the functional properties of fermentation-related ingredients essential for its healthcare business, which encompasses both food and cosmetic applications. The company is also focusing on the formulation of new products through combinations with other aging care materials and innovative technologies.

Healthcare Business: Aging Care Supplements

Alongside its research efforts, Regenerosome is dedicated to the practical implementation of aging care technologies in the market. Its first product, the SAISEI Regenerosome Supplement, which contains a high dose of ergothioneine, was launched in June 2025. This supplement has been developed based on guidelines from the European Food Safety Authority (EFSA).

SAISEI Regenerosome Supplement Features:

• - Main Ingredients:

- Ergothioneine: 30mg/day (High-content, antioxidant property)
- Euglena Powder: 1g/day (Containing 59 nutrients)
- Sake Lees Powder (from sake fermentation)
- Kalahari Watermelon Extract (for moisture retention and antioxidant property)

Future plans include the continued development of next-generation supplements and functional foods centered on aging care.

About Regenerosome

Regenerosome targets the provision of new solutions for aging suppression and regenerative medicine employing nanoparticles such as exosomes. Through in-depth analysis of the exosomes produced by various cells, the startup aims to understand how these nanoparticles function biologically by designing them molecularly. This initiative aspires to develop medical technologies using nanoparticles and propose novel solutions in the field of space medicine—contributing to extended healthy lifespans and humanity's efforts in space exploration.

For further details, visit Regenerosome Website.

About Space Seed Holdings

Space Seed Holdings operates as a venture builder focused on deep tech in the space sector. Their mission integrates investment, research, and business creation activities, particularly through the management of the